Dipyridamole (DPR) is a vasodilator and antiplatelet drug that was marketed in 1963. 1 The drug has been used in the long-term treatment of angina pectoris based on the belief that the drug would reduce anginal episodes, improve exercise tolerance, and reduce medication requirements. Eventually the drug was found to be ineffective in the treatment of angina pectoris. 12 Dipyridamole is indicated for use as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement.2 A number of prosthetic valve studies have shown that the addition of DPR to warfarin further reduces embolic episodes without increasing the bleeding risk. 3 Dipyridamole's use has limitations. Even with use in patients with prosthetic heart valves, it should not be used alone, without an oral anticoagulant, or for the prevention of postoperative thromboembolic complications. 
RESULTS
The age and gender of subjects studied and those reporting the use of DPR at the first (1978) (1979) , seventh (1984) (1985) , and 14th (1991) (1992) Figure 1 . Additionally, the percent of DPR users who also reported the concurrent use of a coumarin anticoagulant drug is shown in Figure 1 . The percent of participants using DPR increased from 1.6% in 1978-1979 to 3.4% in 1991-1992. The highest prevalence of DPR use (7.3%) occurred in the 1986-1987 time period while the lowest prevalence was in 1978-1979.
To determine if there was a change in DPR prescribing over this 14-year period, two mutually exclusive groups were compared. There were 1,843 subjects screened in the program in [1978] [1979] One limitation of this study is that the indication for DPR use in these subjects could not be ascertained. Since no information was available on participants who have had heart valve replacement, appropriateness of DPR use even when the drug was used in combination with coumarin anticoagulants could not be determined.
In summary, most DPR use in these elderly subjects appears to be unwarranted and many elderly subjects are being subjected to the risk of drug exposure without potential benefit. Educational programs are needed to improve the use of DPR in elderly subjects.
